

Industry:

Knowledge Learning & Reasoning Systems, SaaS, Data Services, Machine Learning & Artificial Intelligence for Biomedical, Life Sciences, Health Care & Applied Sciences industries

Management:

- * Anthony Prestigiaco: CEO
- * Rajnish Gupta; CTO / CPO
- * Dr. John Prestigiaco, MD MBA; CSO, Acting CFO
- * Karen Rands; Investor Relations, Business Development Manager

Net Revenues:

- Based on 42 Month Projections
- * Months 1 to 12: \$ (1,630,000)
 - * Months 13 to 24: \$ 25,600,000
 - * Months 25 to 36: \$ 387,700,000
 - * Months 37 to 42: \$ 451,500,000

Current Debt:

None

Previous Investment:

Founder Startup Funding. Integration and commercialization of 12 years R&D by Araicom Research.

See "How it Works" at BioCaid.com to review key value proposition and features from prior prototype systems and research.


Financing Sought:

Convertible Note into \$3.6 Million Series A PPM

Use of Proceeds

- * Commercialization of BioCAID IMDI platform technology & user applications
- * Testing of the SaaS platform & user application interface
- * Patent filings with innovation disclosures for strategic research
- * Go to market sales strategy refinement & implementation
- * Partner negotiation & agreements
- * Market entry and product launch into profitable operations
- * Research grant RFP opportunities

Profiler Family Visualization & Navigation



BioCAID, INC:

BioCAID is revolutionizing how artificial intelligence and machine learning are harnessed to build a new generation of Assistive knowledge services extending user awareness and grasp of comprehension across silos of information and expertise in Biomedical, Life Sciences, Healthcare and related sciences. Our proprietary technologies deliver intelligent semantic frameworks and computational services wrapped around scientific repositories integrated with BioCAID Profiler applications for Freemium, Basic Plus, Professional and Enterprise users. Profiler applications go beyond legacy search to assist users with intuitive visual navigation of relationships between term concepts, and how those terms relate to text/data repositories and user interests to improve access and comprehension of complex scientific libraries and publications. Professional versions deliver literature discovery and hypotheses decision support to assist user access, understanding and insight driving innovation ROI.

Unique Value Proposition:

BioCAID's Intelligent MEDLINE Discovery Integration (IMDI) platform catalogs 2.4 million biomedical term as concepts for Profiler user access, comprehension and discovery of hidden and unknown relationships across scientific literatures such as the National Institutes of Health MEDLINE database of 28 million scientific publications and similar repositories such as academic and drug company research libraries. BioCAID will roll out a 3-year product roadmap of successively sophisticated Profiler application conceptual knowledge services with unique semantic concept visualization, navigation and curation. Initial product launch supports a simplified "Freemium" application with Adwords revenue model targeting 6.8 million monthly Internet Home Health Search (HHS) users identified by Google as seeking scientific publication and library sources. "Profiler Basic Plus" application targets the Scholar market, evolving into Professional and Enterprise applications supporting the more sophisticated needs of professional researchers and enterprise platforms. The 6.8 million Freemium HHS users seeking scientific literature represents an untapped segment of the 165 million Internet healthcare user community BioCAID intends to pioneer and lead.

Key Success Factors:

- Prototype versions of the IMDI platform & user application have been built, tested and validated in peer reviewed research publications. Demonstration and peer review reports available on request.
- IMDI and Profiler applications will save massive amount of time for users with significant Return on Investment for professional and academic researchers.

BioCAID, Inc

Target Markets

- * Home Health Search (HHS) Consumers (165M)
- * Universities & Teaching Hospitals
- * Pharmaceutical Companies
- * Research Facilities
- * Independent Researchers (10M)
- * Doctors & Medical Professionals (7M)

Team Recruitment

- * Digital Marketing Expertise
- * Enterprise Sales Expertise
- * Operations
- * Interim CFO & CMO
- * Customer Service

Product Launch

- * Beta in 6 months after seed round.
- * Freemium version in 12 months and A round funding
- * Basic Plus released month 17
- * Professional released month 25
- * Enterprise released month 36

Mission

Expand the user's reach of awareness and grasp of comprehension across diverse silos of information and fields of expertise, to enhance user access to and identification of relevant information.

Or, more simply, we strive to compound your knowledge by assisting user innovation discovery and outcomes for improved Return on Investment.

To Engage and Learn More about our investment opportunity, visit our website and click on the Investor Relations Tab. Click on Demo & Info tab for video replay of alpha version searching on "headache" and the semantic discovery of related topics.

Key Success Factors:

- ⌵ An active IP portfolio and patent value chaining strategy supersedes other semantic search and discovery tools with a shared IMDI knowledge platform featuring Associative AI and computational algorithms for learning and reasoning supporting assistive Profiler application technologies.
- ⌵ Currently no competitive solutions for semantic search and discovery with integrated visualization, navigation and curation for MEDLINE and similar repositories.
- ⌵ Freemium launch to 6.8 million Internet HHS market achieves profitability 20 months from Series A funding.
- ⌵ Enterprise version will have an option for private labeling for full control by public and privately-operated research

David de Graaf, Pfizer Data Mining Manager estimates \$18 billion is spent per year on compounds that never reach market, while \$30 billion is spent replicating what is already in the literature.

Key Risk Factors:

- ⌵ Inadequate funding to complete commercialization and development for initial product launch. Failure to engage National Institutes of Health, Oakridge National Labs, or Research Universities
- ⌵ Go-To-Market strategy implementation and conversion of users takes longer than anticipated.
- ⌵ Product plan to develop and deploy full multi-product platform is delayed, impacting the effect of the projected reoccurring and compounding revenue targets.

Status:

- ⌵ Key IP licenses and patent assignments have been negotiated including an active development schedule for multiple new patentable innovations to be filed with funding and development.
- ⌵ Prototypes developed, tested and peer reviewed; commercial platform design has been completed with validation and component testing. Commercial development begins with funding.

Business Model:

Initial revenues are derived from monetizing the Freemium version of the IMDI SaaS platform as a consumer oriented intelligent search engine for the PubMed data repository for HHS users and unfunded researchers. IMDI will offer upgrade paths to subscription versions which support cross-silo Comprehension, Literature Discovery, and Hypotheses Decision Support for academic and professional research users. With the paid for versions of IMDI's Profiler families of Basic, Professional and Enterprise user applications and platform products, subscribers will experience the advanced capabilities of the intelligent tool capable of learning from the collective knowledge of the users as they search and experience the power of associated semantic discovery. BioCAID will incorporate two back-end Data Service platforms to expand internal IMDI learning and reasoning technologies. These IMDI platforms will also be monetized for optimal market positioning as Data Services for a variety of Business to Business (B2B) applications and partnering opportunities BioCAID will develop to expand into other industries.

Exit Strategy:

IPO or Acquisition by a search portal, STM publisher or software company.

Documents Available:

Corporate Documents, Business Plan, Market Strategy, Competition, Sales Projections, IP Portfolio, Scientific publications and presentations.

THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR ANY STATE SECURITIES LAWS. THIS SUMMARY SHEET DOES NOT REPRESENT AN OFFER TO SELL ANY SECURITIES. This term sheet includes projections which may and may not be achieved. For full information you must request and review a copy of our complete private placement memorandum.